DelveInsight’s, “Viral Core Protein Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Viral Core Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Viral Core Protein Inhibitors: Overview
The core or capsid protein is essential to virion assembly and structure, interacts with several host cell proteins, and is the most conserved of all of the viral proteins across the six major genotypes. The core protein oligomerizes during the process of viral assembly, and a screen evaluating dimerization, a process mediated by the N-terminal domain, identified small-molecule inhibitors from a library of indoline derivatives. Core inhibitors, also known as capsid assembly modulators or core protein allosteric modulators, are a novel class of HBV replication inhibitors that have been shown to act at multiple steps in the HBV lifecycle.
The companies and academics are working to assess challenges and seek opportunities that could influence Viral Core Protein Inhibitors R&D. The therapies under development are focused on novel approaches for Viral Core Protein Inhibitors.
This segment of the Viral Core Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Viral Core Protein Inhibitors Emerging Drugs
Vebicorvir: Assembly Biosciences
Vebicorvir, first-generation core inhibitor is being developed by Assembly Biosciences. In Phase 2 clinical trials, first-generation core inhibitor vebicorvir (VBR) administered with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy demonstrated a favorable safety profile and led to greater viral suppression of both HBV DNA and HBV pgRNA than NrtI therapy alone. VBR is advancing in multiple Phase 2 combination studies. Vebicorvir have been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of chronic HBV infection.
Morphothiadine: HEC Pharm
Morphothiadine (GLS4), a HAP (heteroaryl-di-hydro-pyrimidines) compound is being developed by HEC Pharm Group, for the oral treatment of hepatitis B.
Further product details are provided in the report……..
This segment of the report provides insights about the different Viral Core Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the Viral Core Protein Inhibitors. The companies which have their Viral Core Protein Inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Assembly Biosciences.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Viral Core Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Viral Core Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Viral Core Protein Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Viral Core Protein Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Viral Core Protein Inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Vebicorvir: Assembly Biosciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
EDP 514: Enanta Pharmaceuticals
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
ABI 4334: Assembly Biosciences
Drug profiles in the detailed report…..
Inactive Products
Viral Core Protein Inhibitors Key Companies
Viral Core Protein Inhibitors Key Products
Viral Core Protein Inhibitors- Unmet Needs
Viral Core Protein Inhibitors- Market Drivers and Barriers
Viral Core Protein Inhibitors- Future Perspectives and Conclusion
Viral Core Protein Inhibitors Analyst Views
Viral Core Protein Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Viral Core Protein Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Viral Core Protein Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Assembly Biosciences
• HEC Pharm
• Janssen Sciences Ireland
• Enanta Pharmaceuticals
• Fujian Cosunter Pharmaceutical
• Door Pharmaceuticals
